Mesalamine in Crohn's disease with steroid-induced remission: Effect on steroid withdrawal and remission maintenance, Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives

Modigliani, R; Colombel, J F; Jl, Dupas; Dapoigny, Michel; Costil, Vianna; Veyrac, M.; Duclos, Bernard; Soulé, J C; Jp, Gendre; Jp, Galmiche; Danne, O; Cadiot, Guillaume; Lamouliatte, H; Belaiche, J; Mary, J Y

doi:10.1053/gast.1996.v110.pm8608877

Cited by 145 publications

(71 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…ere are no short-or long-term bene ts from the addition of aminosalicylates to corticosteroids (92,125,126) . Azathioprine and 6-mercaptopurine have had demonstrable adjunctive bene ts to steroids in adults (number needed to treat (NNT) = 5) (127,128) .…”

Section: Mild To Moderate Active Diseasementioning

confidence: 99%

See 1 more Smart Citation

Management of Crohn's Disease in Adults

2009

View full text Add to dashboard Cite

Guidelines for clinical practice are intended to suggest preferable approaches to particular medical problems as established by interpretation and collation of scientifi cally valid research, derived from extensive review of published literature. When data that will withstand objective scrutiny are not available, a recommendation may be made based on a consensus of experts. Guidelines are intended to apply to the clinical situation for all physicians without regard to specialty. Guidelines are intended to be fl exible, not necessarily indicating the only acceptable approach, and should be distinguished from standards of care that are infl exible and rarely violated. Given the wide range of choices in any health-care problem, the physician should select the course best suited to the individual patient and the clinical situation presented. These guidelines are developed under the auspices of the American College of Gastroenterology and its Practice Parameters Committee. Expert opinion is solicited from the outset for the document. The quality of evidence upon which a specifi c recommendation is based is as follows: Grade A: Homogeneous evidence from multiple well-designed randomized (therapeutic) or cohort (descriptive) controlled trials, each involving a number of participants to be of suffi cient statistical power. Grade B: Evidence from at least one large well-designed clinical trial with or without randomization, from cohort or case -control analytic studies, or well-designed meta-analysis. Grade C: Evidence based on clinical experience, descriptive studies, or reports of expert committees. The Committee reviews guidelines in depth, with participation from experienced clinicians and others in related fi elds. The fi nal recommendations are based on the data available at the time of the production of the document and may be updated with pertinent scientifi c developments at a later time.

show abstract

Section: Mild To Moderate Active Diseasementioning

confidence: 99%

“…In particular, mesalamine (at a dose of 4 g daily) has not been e cacious in preventing relapse a er corticosteroid-induced remissions (125) . Antibiotics as an agent for maintenance of medically induced remission have not been evaluated.…”

Section: Maintenance Therapymentioning

confidence: 99%

Management of Crohn's Disease in Adults

2009

View full text Add to dashboard Cite

show abstract

“…Other side effects include hemolytic anemia and pruritic dermatitis. The newer mesalamine preparation, pentasa, has been used for small bowel CD to facilitate steroid withdrawal and to reduce relapse rates following steroid withdrawal (74).…”

Section: Medical Management Of Crohn's Diseasementioning

confidence: 99%

Clinical Aspects and Pathophysiology of Inflammatory Bowel Disease

2002

View full text Add to dashboard Cite

SUMMARY The chronic inflammatory bowel diseases (IBD), Crohn's disease and ulcerative colitis, are recognized as important causes of gastrointestinal disease in children and adults. In this review we delineate the clinical manifestations and diagnostic features of IBD. In addition, we summarize important recent advances in our understanding of the immune mediators of intestinal inflammation. This information has led to new therapeutic approaches in IBD. Further, we discuss the considerable data that point to the significance of genetic factors in the development of IBD and the genetic loci which have been implicated through genomewide searches. The commensal bacterial flora also appears to be a critical element, particularly in regards to Crohn's disease, although the precise role of the bacteria in the disease manifestations remains unclear. Current investigations promise to yield fresh insights in these areas.

show abstract

“…In this literature review, we have selected five studies which showed a favorable effect of 5-ASA [11,12,13,14,15], four studies which did not show that 5-ASA prevented relapse [16,17,18,19] and, finally, three meta-analyses which appeared in 1994 and 1997 were also examined [20,21,22]. …”

Section: Treatmentmentioning

confidence: 99%

Maintenance of Remission in Crohn’s Disease

et al. 2005

View full text Add to dashboard Cite

When remission of Crohn’s disease is achieved, the next goal is to maintain long-term remission. Aminosalicylates may be recommended for maintenance remission, even though the results are less consistent than those observed in ulcerative colitis. The benefit is mainly observed in the post-surgical setting and in patients with ileitis, and with a prolonged disease duration. Corticosteroids are not effective in maintaining remission and should not be used for this indication. Azathioprine and 6-mercaptopurine are effective in maintaining remission. Maintenance benefits remain significant for patients who continued with the therapy for up to 5 years. Methotrexate has also been found to be effective in maintaining remission in Crohn’s disease in patients who have responded acutely to methotrexate. Cyclosporine has not been found to be an effective maintenance agent. Mycophenolate mofetil could be considered a therapy in patients who are either allergic to azathioprine or in whom azathioprine failed to induce remission. The use of infliximab may change the future approach to maintenance therapy for Crohn’s disease. Patients who responded clinically to infliximab have maintained their clinical response when receiving repeat infusions at 8-week intervals. In patients refractory to other therapies, infliximab may be effective in maintaining remission.

show abstract

Mesalamine in Crohn's disease with steroid-induced remission: Effect on steroid withdrawal and remission maintenance, Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives

Cited by 145 publications

References 4 publications

Management of Crohn's Disease in Adults

Management of Crohn's Disease in Adults

Clinical Aspects and Pathophysiology of Inflammatory Bowel Disease

Maintenance of Remission in Crohn’s Disease

Contact Info

Product

Resources

About